Conference Details - Agenda
View all Conferences
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Sixth Annual Symposium on Controversies and Clinical Challenges In Lymphoma, Myeloma, and Leukemia
Pointe Hilton Tapatio Cliffs
Phoenix, AZ
September 11-12, 2009
Friday, Sep 11, 2009
| 7:30 am | Registration and Continental Breakfast |
| 7:55 am | Welcome and Introductions |
| 8:00 am | Presession Survey |
| 8:05 am | Keynote Presentation: From Bench to Bedside in Hematologic Malignancies Thomas P. Miller |
| Clinical Challenges in Lymphoma Moderator: Thomas P. Miller |
|
| 8:35 am | Clinical Challenges in Low-Grade Lymphoma John Sweetenham |
| 8:55 am | Clinical Challenges in DLBCL Thomas P. Miller |
| 9:15 am | Clinical Challenges in MCL André Goy |
| 9:35 am | Clinical Challenges in TCLs Barbara Pro |
| 9:55 am | Panel Discussion |
| 10:15 am | Break |
| Controversies in Lymphoma Moderator: Thomas P. Miller |
|
| Debate: Intensive Versus Nonintensive Therapies in Mantle Cell Lymphoma |
|
| 10:30 am | Intensive Michele Fanale |
| 10:50 am | Nonintensive André Goy |
| 11:10 am | Clinical Challenges in Treating Elderly Patients With DLBCL John Sweetenham |
| 11:30 am | Lymphoma Therapy: The Next Decade Wyndham H. Wilson |
| 11:50 am | Postsession Survey and Panel Discussion |
| 12:10 pm | Break to Serve Lunch |
| 1:05 pm | Keynote Presentation: Targeting Cancer Stem Cells in Hematologic Malignancies Farhad Ravandi |
| Clinical Challenges in CLL Moderator: Stefan Faderl |
|
| 1:40 pm | Presession Survey |
| 1:45 pm | Pathologic Subtypes of CLL: Clinical Implications Parameswaran Venugopal |
| 2:10 pm | Challenges in Frontline Therapy for CLL Nicole Lamanna |
| 2:35 pm | Challenges in Salvage Treatment in CLL Stefan Faderl |
| 3:00 pm | New Agents on the Horizon for CLL Jeffrey Jones |
| 3:25 pm | Postsession Survey and Case-Based Panel Discussion: Applying Principle to Practice Stefan Faderl |
| 4:00 pm | Tumor Board: Curbside Consultations |
| 5:00 pm | Adjourn |
Educational Grants
An educational grant for this activity was provided by:
- Cephalon Oncology
- Merck Oncology
- Millennium Pharmaceuticals, Inc.
- Novartis Oncology
- Celgene Corporation